Could | The Knowledge Dynasty


Experts suggest Artificial Intelligence could treat individuals based on genes

Experts suggest Artificial Intelligence could treat individuals based on genes
The hand of humanoid robot AILA (artificial intelligence lightweight android) operates a switchboard during a demonstration by the German research centre for artificial intelligence at the CeBit computer fair in Hanover March, 5, 2013. The biggest fair …
Read more on International Business Times AU

New Discovery Could Make Production of Medicines, New Materials and Other Essential Items Cheaper and Greener

Pasadena, CA (PRWEB) April 20, 2015

When Caltech PhD candidate Anton Toutov observed that a commonly available salt was serving as a catalyst for an important chemical process, he couldn’t believe his findings. If this worked, he knew, it could set the chemical industry on a safer and more environmentally sound path.

Over a century ago, it was discovered that special additives called catalysts could accelerate chemical reactions. This discovery gave rise to the modern chemical industry, and today catalysts are used in the production of nearly 90% of the world’s chemical consumer and industrial goods – everything from lifesaving drugs to materials for ultra-efficient solar panels and more. However, many catalysts are made from precious metals like gold and platinum, which are expensive and also produce toxic waste streams. Toutov’s unexpected discovery of an inexpensive and biodegradable potassium catalyst could change all of that.

“To be honest, I didn’t believe the data when Anton first showed it to me,” said Toutov’s faculty mentor Dr. Robert H. Grubbs, Nobel Prize winner and Victor and Elizabeth Atkins Professor of Chemistry at Caltech. “It will take time, and it will be an exciting and challenging road ahead, but ultimately this discovery offers a simpler, more affordable and sustainable route towards making many essential chemical products.”

Today, the Resnick Sustainability Institute at Caltech has released a short film, Element 19 (which is the number for potassium on the periodic table) (, to explain the implications of Toutov’s discovery. (Described in more scientific detail in Caltech’s news feature at and in the team’s Nature article). Shot on location at Caltech and featuring Toutov, Stoltz and Grubbs, among others involved in the discovery, it was produced by the creative teams of M. Samuels Media ( and Oshin Studio: ( along with Toutov, a Dow-Resnick Fellow at Caltech’s Resnick Sustainability institute.

At the heart of the film, is Toutov’s discovery that an abundant and inexpensive potassium-based material that looks like ordinary table salt can be used as a catalyst for one of the most studied chemical reactions of the past decade.

There are a variety of significant benefits of this discovery: the potassium catalyst is renewable (it can be made entirely from plant matter), non-toxic, biodegradable, and, considerably less expensive than the precious metal catalysts currently used in the production of consumer goods. Importantly, manufacturers can start using the technology immediately since it requires no new infrastructure or training to implement.

Compared to today’s precious metal catalysts, the cost of the new potassium catalyst can be anywhere from hundreds to tens of thousands of times less expensive. The considerable financial incentive is an enormous enabler for companies to start using this technology to produce everything from space-age materials and substances that safely protect crops from disease all the way to perfumes and cosmetics in an environmentally friendly manner.

“With this catalyst, we have finally shown that truly sustainable chemistry may actually be possible,” said Toutov, adding that potassium is about 25 million times more abundant on Earth than precious metal elements (which mean that while current catalyst materials like platinum and palladium are at risk of depletion, potassium will be plentiful in the centuries to come).

“It was very brave to pursue this research; it looks at the problem in different ways than ever before,” said Brian M. Stoltz, Caltech Professor of Chemistry. “Everybody is shocked and amazed. It could be a real game-changer and ultimately will lead to safer, less toxic, and overall more sustainable production of the everyday products that we depend on.”

About The Resnick Sustainability Institute

The Resnick Institute is Caltech’s studio focused on the breakthroughs that will change the balance of the world’s sustainability. It marries bold creativity and deep scientific knowledge by encouraging original thinking and orthogonal ideas. The Resnick Institute works with some of the world’s top and emerging scientists – at the California Institute of Technology and beyond. Current projects at the Resnick Institute include research into energy generation, such as advanced photovoltaics, photoelectrochemical solar fuels, cellulosic biofuels, and wind energy system design; energy conversion work on batteries and fuel cells; and energy efficiency and management such as fuel efficient vehicles, green chemical synthesis, thermoelectric materials, and advanced research on electrical grid control and distribution.

For more information, visit


Editors, note: All trademarks and registered trademarks are those of their respective companies.

Additional background information is available at

More Chemistry Press Releases

Reduction of effective dose of statins, by liver targeting delivery, could be a way to bring the drugs to the prevention market – proof-of-concept trial by Lycotec Ltd.

Statins are one of the most successful drugs able to slow down the formation of cholesterol-rich atherosclerotic plaques on the arterial walls, and reduce the development of and mortality from coronary heart disease, CHD.

Although their efficacy in management of elevated LDL cholesterol and CHD is not questionable, recommendation of their use for preventative purposes for healthy people or even borderline conditions is a subject of an ongoing strong debate.

Statins like many other drugs have their own side-effects. The use of them for people with elevated cholesterol or with already established CHD overpowers these side-effects. However, the use of statins for preventative purposes with possibilities to develop, albeit not too frequent, but still negative reactions, remains controversial.

The main reason behind the side-effects is the distribution and accumulation of statins outside their main target, the liver, into skeletal muscles or other organs.

Lycotec Ltd., the Cambridge UK based biotech company has developed and patented liver targeting oral delivery technology, LycosomeTM –

Based on this technology, the company has created a prototype, LycoStatinTM.

In a double blind study 40 volunteers with elevated LDL cholesterol were randomised and distributed in 5 groups with 8 participants each. The first three groups received daily either 20, or 40 or 80 mg of Simvastatin. The fourth group received LycoStatinTM containing 20 mg of Simvastatin. and the fifth group received a control lycopene, the carotenoid with is used to make Lycosomes, in the same dose as in the fourth group.

After one month of the trial it was shown that the level of the reduction of LDL cholesterol in the fourth group was significantly stronger than in the groups taking 20 or 40 mg of Simvastatin, and was at the same level as in the group which was taking 80 mg of the drug. There were no changes in LDL level in the fifth group.

These preliminary results indicate that the liver targeting delivery could increase the efficacy of statins, by apparent reduction of their random distribution to other organs, which are not involved in LDL synthesis, hence potentially minimise the side-effects of these drugs.

Some results of this trial have now been published in a peer review journal as a State of the Art Paper:

Later this week the Lycotec team, Dr Ivan Petyaev and Dr Yuiry Bashmakov, will present the LycoStatinTM at the World Liver Targeting Conference in Malta:

The company believes that reducing the effective dose of statins, minimising their potential side-effects, would allow these drugs, which have already saved millions of lives of people with CHD, to expand their benefit to even more millions of healthy people to prevent the development of this dominating killer disease in the developed world.

Lycotec is now looking for pharmaceutical industry partnership to further develop LycoStatin and bring it, and its potential range, to the CHD preventative market.

Related Technology Press Releases

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.



New Skills, New You: Transform your career in 2016 with Coursera

Follow us on Twitter